Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Evolving Treatment Approaches

Posted: Tuesday, December 4, 2018

Shaji K. Kumar, MD, of the Mayo Clinic, describes—and places into context—the phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who are ineligible for transplant.